신장 바이오마커 시장 보고서 : 바이오마커 유형, 진단 기술, 최종 사용자, 지역별(2026-2034년)

The global renal biomarkers market size reached USD 1.5 Billion in 2025. Looking forward, IMARC Group expects the market to reach USD 2.7 Billion by 2034, exhibiting a growth rate (CAGR) of 6.28% during 2026-2034. The increasing public health concerns and its main risk factors, including hypertension, diabetes, and heart diseases, are bolstering the market.

Renal biomarkers are cells, proteins, lipids, microRNAs, genes, metabolites, or proteomic patterns present on a urinalysis. They assist in determining the glomerular filtration rate (GFR) of kidneys to analyze their proper functioning and evaluating pathogenic processes or pharmacological responses to therapeutic interventions. As they also aid in predicting disease progression and computing drug dosage, renal biomarkers find extensive applications in hospitals and diagnostic laboratories across the globe.

Renal Biomarkers Market Trends:

Chronic kidney disease (CKD), non-communicable disease with considerable morbidity and mortality, has gradually become a public health concern globally and its main risk factors are diabetes, hypertension and heart diseases. The increasing number of individuals with CKD represents one of the key factors propelling the growth of the market. Moreover, renal biomarkers, including blood urea nitrogen (BUN), serum creatinine (SCr), urinary albumin/protein and volume excretion, are used in the diagnosis of chronic kidney disease (CKD) and monitoring of the disease. Besides this, there is a growing interest of industry investors in novel single biomarkers and process-specific biomarker panels in human renal diseases around the world. These novel biomarkers provide vital diagnostic and prognostic information and help predict response to the treatment of glomerulopathies, acute kidney injury (AKI), and autosomal dominant polycystic kidney disease (ADPKD). Apart from this, renal biomarkers are becoming accessible and feasible in all-sized laboratories. This, along with the development and integration of genomics, epigenetics, transcriptomics, proteomics, and metabolomics, is positively influencing the market. Some of the other factors, such as the burgeoning healthcare industry, the rising geriatric population, and the increasing number of clinical trials for CKD worldwide, are anticipated to facilitate the growth of the market.

Market Segmentation:

This report provides an analysis of the key trends in each segment of the market, along with the renal biomarkers market forecast at the global, regional, and country levels for 2026-2034. The report categorizes the market based on the biomarker type, diagnostic technique, and end user.

Breakup by Biomarker Type:

• Functional Biomarker
• Serum Creatinine
• Serum Cystatin C
• Urine Albumin
• Up-regulated Protein
• Neutrophil Gelatinase-Associated Lipocalin (NGAL)
• Kidney Injury Molecule-1
• INTERLEUKIN-18
• Others

Breakup by Diagnostic Technique:

• Enzyme-linked Immunosorbent Assay (ELISA)
• Particle-enhanced Turbidimetric Immunoassay (PETIA)
• Colorimetric Assay
• Chemiluminescent Enzyme Immunoassay (CLIA)
• Liquid Chromatography Mass Spectrometry (LC-MS)

Breakup by End User:

• Hospital
• Diagnostic Laboratory
• Others

Breakup by Region:

• North America
• United States
• Canada
• Asia-Pacific
• China
• Japan
• India
• South Korea
• Australia
• Indonesia
• Others
• Europe
• Germany
• France
• United Kingdom
• Italy
• Spain
• Russia
• Others
• Latin America
• Brazil
• Mexico
• Others
• Middle East and Africa

Competitive Landscape:

The competitive landscape of the industry has also been examined along with the profiles of the key players being Abbott Laboratories, Beckman Coulter Inc. (Danaher Corporation), bioMerieux SA, BioPorto A/S, Bio-Rad Laboratories Inc., Enzo Biochem Inc., F. Hoffmann-La Roche AG, PerkinElmer Inc., Randox Laboratories Ltd., Siemens AG and Thermo Fisher Scientific Inc.

Key Questions Answered in This Report

1. What was the size of the global renal biomarkers market in 2025?

2. What is the expected growth rate of the global renal biomarkers market during 2026-2034?

3. What has been the impact of COVID-19 on the global renal biomarkers market?

4. What are the key factors driving the global renal biomarkers market?

5. What is the breakup of the global renal biomarkers market based on the biomarker type?

6. What is the breakup of the global renal biomarkers market based on the diagnostic technique?

7. What is the breakup of the global renal biomarkers market based on end user?

8. What are the key regions in the global renal biomarkers market?

9. Who are the key players/companies in the global renal biomarkers market?

Table of Contents

1 Preface

2 Scope and Methodology

• 2.1 Objectives of the Study
• 2.2 Stakeholders
• 2.3 Data Sources
  • 2.3.1 Primary Sources
  • 2.3.2 Secondary Sources
• 2.4 Market Estimation
  • 2.4.1 Bottom-Up Approach
  • 2.4.2 Top-Down Approach
• 2.5 Forecasting Methodology

3 Executive Summary

4 Introduction

• 4.1 Overview
• 4.2 Key Industry Trends

5 Global Renal Biomarkers Market

• 5.1 Market Overview
• 5.2 Market Performance
• 5.3 Impact of COVID-19
• 5.4 Market Forecast

6 Market Breakup by Biomarker Type

• 6.1 Functional Biomarker
  • 6.1.1 Market Trends
  • 6.1.2 Key Segments
    • 6.1.2.1 Serum Creatinine
    • 6.1.2.2 Serum Cystatin C
    • 6.1.2.3 Urine Albumin
  • 6.1.3 Market Forecast
• 6.2 Up-regulated Protein
  • 6.2.1 Market Trends
  • 6.2.2 Key Segments
    • 6.2.2.1 Neutrophil Gelatinase-Associated Lipocalin (NGAL)
    • 6.2.2.2 Kidney Injury Molecule-1
    • 6.2.2.3 INTERLEUKIN-18
  • 6.2.3 Market Forecast
• 6.3 Others
  • 6.3.1 Market Trends
  • 6.3.2 Market Forecast

7 Market Breakup by Diagnostic Technique

• 7.1 Enzyme-linked Immunosorbent Assay (ELISA)
  • 7.1.1 Market Trends
  • 7.1.2 Market Forecast
• 7.2 Particle-enhanced Turbidimetric Immunoassay (PETIA)
  • 7.2.1 Market Trends
  • 7.2.2 Market Forecast
• 7.3 Colorimetric Assay
  • 7.3.1 Market Trends
  • 7.3.2 Market Forecast
• 7.4 Chemiluminescent Immunoassay (CLIA)
  • 7.4.1 Market Trends
  • 7.4.2 Market Forecast
• 7.5 Liquid Chromatography Mass Spectrometry (LC-MS)
  • 7.5.1 Market Trends
  • 7.5.2 Market Forecast

8 Market Breakup by End User

• 8.1 Hospital
  • 8.1.1 Market Trends
  • 8.1.2 Market Forecast
• 8.2 Diagnostic Laboratory
  • 8.2.1 Market Trends
  • 8.2.2 Market Forecast
• 8.3 Others
  • 8.3.1 Market Trends
  • 8.3.2 Market Forecast

9 Market Breakup by Region

• 9.1 North America
  • 9.1.1 United States
    • 9.1.1.1 Market Trends
    • 9.1.1.2 Market Forecast
  • 9.1.2 Canada
    • 9.1.2.1 Market Trends
    • 9.1.2.2 Market Forecast
• 9.2 Asia-Pacific
  • 9.2.1 China
    • 9.2.1.1 Market Trends
    • 9.2.1.2 Market Forecast
  • 9.2.2 Japan
    • 9.2.2.1 Market Trends
    • 9.2.2.2 Market Forecast
  • 9.2.3 India
    • 9.2.3.1 Market Trends
    • 9.2.3.2 Market Forecast
  • 9.2.4 South Korea
    • 9.2.4.1 Market Trends
    • 9.2.4.2 Market Forecast
  • 9.2.5 Australia
    • 9.2.5.1 Market Trends
    • 9.2.5.2 Market Forecast
  • 9.2.6 Indonesia
    • 9.2.6.1 Market Trends
    • 9.2.6.2 Market Forecast
  • 9.2.7 Others
    • 9.2.7.1 Market Trends
    • 9.2.7.2 Market Forecast
• 9.3 Europe
  • 9.3.1 Germany
    • 9.3.1.1 Market Trends
    • 9.3.1.2 Market Forecast
  • 9.3.2 France
    • 9.3.2.1 Market Trends
    • 9.3.2.2 Market Forecast
  • 9.3.3 United Kingdom
    • 9.3.3.1 Market Trends
    • 9.3.3.2 Market Forecast
  • 9.3.4 Italy
    • 9.3.4.1 Market Trends
    • 9.3.4.2 Market Forecast
  • 9.3.5 Spain
    • 9.3.5.1 Market Trends
    • 9.3.5.2 Market Forecast
  • 9.3.6 Russia
    • 9.3.6.1 Market Trends
    • 9.3.6.2 Market Forecast
  • 9.3.7 Others
    • 9.3.7.1 Market Trends
    • 9.3.7.2 Market Forecast
• 9.4 Latin America
  • 9.4.1 Brazil
    • 9.4.1.1 Market Trends
    • 9.4.1.2 Market Forecast
  • 9.4.2 Mexico
    • 9.4.2.1 Market Trends
    • 9.4.2.2 Market Forecast
  • 9.4.3 Others
    • 9.4.3.1 Market Trends
    • 9.4.3.2 Market Forecast
• 9.5 Middle East and Africa
  • 9.5.1 Market Trends
  • 9.5.2 Market Breakup by Country
  • 9.5.3 Market Forecast

10 SWOT Analysis

• 10.1 Overview
• 10.2 Strengths
• 10.3 Weaknesses
• 10.4 Opportunities
• 10.5 Threats

11 Value Chain Analysis

12 Porters Five Forces Analysis

• 12.1 Overview
• 12.2 Bargaining Power of Buyers
• 12.3 Bargaining Power of Suppliers
• 12.4 Degree of Competition
• 12.5 Threat of New Entrants
• 12.6 Threat of Substitutes

13 Price Analysis

14 Competitive Landscape

• 14.1 Market Structure
• 14.2 Key Players
• 14.3 Profiles of Key Players
  • 14.3.1 Abbott Laboratories
    • 14.3.1.1 Company Overview
    • 14.3.1.2 Product Portfolio
    • 14.3.1.3 Financials
    • 14.3.1.4 SWOT Analysis
  • 14.3.2 Beckman Coulter Inc. (Danaher Corporation)
    • 14.3.2.1 Company Overview
    • 14.3.2.2 Product Portfolio
  • 14.3.3 bioMerieux SA
    • 14.3.3.1 Company Overview
    • 14.3.3.2 Product Portfolio
  • 14.3.4 BioPorto A/S
    • 14.3.4.1 Company Overview
    • 14.3.4.2 Product Portfolio
    • 14.3.4.3 Financials
  • 14.3.5 Bio-Rad Laboratories Inc.
    • 14.3.5.1 Company Overview
    • 14.3.5.2 Product Portfolio
    • 14.3.5.3 Financials
    • 14.3.5.4 SWOT Analysis
  • 14.3.6 Enzo Biochem Inc.
    • 14.3.6.1 Company Overview
    • 14.3.6.2 Product Portfolio
  • 14.3.7 F. Hoffmann-La Roche AG
    • 14.3.7.1 Company Overview
    • 14.3.7.2 Product Portfolio
    • 14.3.7.3 SWOT Analysis
  • 14.3.8 PerkinElmer Inc.
    • 14.3.8.1 Company Overview
    • 14.3.8.2 Product Portfolio
    • 14.3.8.3 Financials
    • 14.3.8.4 SWOT Analysis
  • 14.3.9 Randox Laboratories Ltd.
    • 14.3.9.1 Company Overview
    • 14.3.9.2 Product Portfolio
  • 14.3.10 Siemens AG
    • 14.3.10.1 Company Overview
    • 14.3.10.2 Product Portfolio
    • 14.3.10.3 Financials
    • 14.3.10.4 SWOT Analysis
  • 14.3.11 Thermo Fisher Scientific Inc.
    • 14.3.11.1 Company Overview
    • 14.3.11.2 Product Portfolio
    • 14.3.11.3 Financials
    • 14.3.11.4 SWOT Analysis